Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Joan Fabregat
Based on 6 articles published since 2009
(Why 6 articles?)
||||

Between 2009 and 2019, Joan Fabregat wrote the following 6 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Guideline [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. 2016

Martin-Richard, Marta / Ginès, Angels / Ayuso, Juan Ramón / Sabater, Luis / Fabregat, Joan / Mendez, Ramiro / Fernández-Esparrach, Glòria / Molero, Xavier / Vaquero, Eva C / Cuatrecasas, Miriam / Ferrández, Antonio / Maurel, Joan / Anonymous3560884. ·Servicio de Oncología Médica, Hospital Sant Pau, Barcelona, España. Electronic address: mmartinri@santpau.cat. · Servicio de Gastroenterología, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Radiología, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Cirugía, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Cirugía, Hospital de Bellvitge, Barcelona, España. · Servicio de Radiología, Hospital Clínico San Carlos, Madrid, España. · Servicio de Gastroenterología, Hospital Vall d'Hebron, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Oncología Médica, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, España. ·Med Clin (Barc) · Pubmed #27726847.

ABSTRACT: BACKGROUND AND OBJECTIVE: Clinical management of adenocarcinoma of the pancreas is complex, and requires a multidisciplinary approach. The same applies for the premalignant lesions that are increasingly being diagnosed. The current document is an update on the diagnosis and management of premalignant lesions and adenocarcinoma of the pancreas. PATIENTS AND METHODS: A conference to establish the basis of the literature review and manuscript redaction was organized by the Grupo Español Multidisciplinar en Cáncer Digestivo. Experts in the field from different specialties (Gastroenterology, Surgery, Radiology, Pathology, Medical Oncology and Radiation Oncology) met to prepare the present document. RESULTS: The current literature was reviewed and discussed, with subsequent deliberation on the evidence. CONCLUSIONS: Final recommendations were established in view of all the above.

2 Clinical Trial Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). 2018

Maurel, Joan / Sánchez-Cabús, Santiago / Laquente, Berta / Gaba, Lydia / Visa, Laura / Fabregat, Joan / Povés, Ignacio / Roselló, Susana / Díaz-Beveridge, Roberto / Martín-Richard, Marta / Rodriguez, Javier / Sabater, Luis / Conill, Carles / Cambray, María / Reig, Ana / Ayuso, Juan Ramón / Valls, Carlos / Ferrández, Antonio / Bombí, Josep Antoni / Ginés, Angels / García-Albéniz, Xabier / Fernández-Cruz, Laureano. ·Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain. jmaurel@clinic.cat. · Surgical Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Medical Oncology Department, Institut Català d'Oncologia, Hospitalet, Spain. · Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain. · Department of Oncology, Hospital Mar, Barcelona, Spain. · Surgical Department, Hospital Bellvitge, Hospitalet, Spain. · Surgical Department, Hospital del Mar, Barcelona, Spain. · Medical Oncology Department, Hospital Clínico Valencia, Valencia, Spain. · Medical Oncology Department, Hospital La Fe, Valencia, Spain. · Medical Oncology Department, Hospital Sant Pau, Barcelona, Spain. · Medical Oncology Department, Hospital Clínico Universitario Navarra, Pamplona, Spain. · Surgical Department, Hospital Clínico Valencia, Valencia, Spain. · Radiotherapy Oncology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Radiotherapy Oncology Department, Institut Català d'Oncologia, Hospitalet, Spain. · Radiotherapy Oncology Department, Hospital Mar, Barcelona, Spain. · Radiology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Radiology Department, Hospital Bellvitge, Hospitalet, Spain. · Pathology Department, Hospital Clínico Valencia, Valencia, Spain. · Pathology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Gastrointestinal Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Harvard T.H. Chan School of Public Health, Boston, MA, USA. · Surgical Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. lfcruz@clinic.cat. ·Cancer Chemother Pharmacol · Pubmed #30225601.

ABSTRACT: BACKGROUND: Neoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) patients has shown promising results in non-randomized trials. This is a multi-institutional phase II trial of NAT in resectable PDAC patients. METHODS: Patients with confirmed resectable PDAC after agreement by two expert radiologists were eligible. Patients received three cycles of GEM (1000 mg/m RESULTS: Twenty-five patients were enrolled. Adverse effects of NAT were mainly mild gastrointestinal disorders. Resectability rate was 76%, with a R0 rate of 63.1% among the resected patients. Median overall survival (OS) and disease-free survival (DFS) were 23.8 (95% CI 11.4-36.2) and 12.8 months (95% CI 8.6-17.1), respectively. R0 resection patients had better median OS, compared with patients with R1 resection or not resected (65.5 months vs. 15.5 months, p = 0.01). N0 rate among the resected patients was 63.1%, and showed a longer median OS (65.5 vs. 15.2 months, p = 0.009). CONCLUSION: The results of this study confirm promising oncologic results with NAT for patients with resectable PDAC. Therefore, the present trial supports the development of phase II randomized trials comparing NAT vs. upfront surgery in resectable pancreatic cancer.

3 Article Is pancreaticoduodenectomy a safe procedure in the cirrhotic patient? 2016

Busquets, Juli / Peláez, Núria / Gil, Marta / Secanella, Lluís / Ramos, Emilio / Lladó, Laura / Fabregat, Joan. ·Servei de Cirurgia General i Digestiva, Hospital Universitari de Bellvitge, Barcelona, España. Electronic address: jbusquets@bellvitgehospital.cat. · Servei de Cirurgia General i Digestiva, Hospital Universitari de Bellvitge, Barcelona, España. ·Cir Esp · Pubmed #27045614.

ABSTRACT: INTRODUCTION: Pancreaticoduodenectomy (PD) is usually contraindicated in chronic liver disease. The objective of the present study was to analyze PD results in cirrhotic patients, and compare them with non-cirrhotic ones. METHODS: Between 1994 and 2014 we prospectively collected all patients with a PD for periampullar neoplasms in Hospital Universitari de Bellvitge. We registered preoperative, intraoperative and postoperative variables. We defined patients undergoing PD with liver cirrhosis as the study group (CH group), and those without liver cirrhosis as the control group (NCH group). A case/control study was performed (1/2). RESULTS: We registered 15 patients in the CH group, all with good liver function (Child A), and included 30 patients in NCH group. The causes of hepatopathy were HCV (60%) and alcoholism (40%). For the 3 moments studied, the CH group had a lower blood platelet count and a higher prothrombin ratio, compared with NCH group. Postoperative morbidity was 60% and mean postoperative stay was 25±19 days, with no differences in terms of complications between CH group and NCG group (73% vs. 53%, P=.1). Presence of ascites was higher in the CH group compared with NCH group (28 vs. 0%, P<.001). There were no differences in terms of hemorrhage or pancreatic fístula. Four patients of the CH group and 2 patients of the NCH group were reoperated on (26.7 vs. 6.7%, P=.1). There was no postoperative mortality. CONCLUSIONS: PD is a safe procedure in cirrhotic patients with good liver function although it presents high morbidity.

4 Article Genetic and epigenetic markers in the evaluation of pancreatic masses. 2013

Ginestà, Mireia M / Mora, Josefina / Mayor, Regina / Farré, Antoni / Peinado, Miquel Angel / Busquets, Juli / Serrano, Teresa / Capellá, Gabriel / Fabregat, Joan. ·Translational Research Laboratory, Hereditary Cancer Program, Institut Català d´Oncologia-IDIBELL, Barcelona, Spain. ·J Clin Pathol · Pubmed #23135349.

ABSTRACT: BACKGROUND: Methylation markers have shown promise in the early diagnosis of pancreatic carcinoma. The aim of this study was to assess the diagnostic utility of hypermethylation status of candidate genes in combination with KRAS mutation detection in the evaluation of pancreatic masses. EXPERIMENTAL DESIGN: Sixty-one fine needle aspirates of pancreatic masses (43 pancreatic adenocarcinomas and 18 chronic pancreatitis) were studied. Methylation status of HRH2, EN1, SPARC, CDH13 and APC were analysed using melting curve analysis after DNA bisulfite treatment. KRAS mutations were also analysed. RESULTS: The methylation panel had a sensitivity of 73% (27 of 37, CI 95% 56 to 86%) and a specificity of 100% whenever two or more promoters were found hypermethylated. KRAS mutations showed a sensitivity of 77% (33 of 43, CI 95% 62 to 88%) and a specificity of 100%. Both molecular analyses added useful information to cytology by increasing the number of informative cases. When genetic and epigenetic analyses were combined sensitivity was 84% (36 of 43 CI 95% 69 to 93%) maintaining a 100% specificity. CONCLUSIONS: Analysis of hypermethylation status of a panel of genes and KRAS mutation detection offer a similar diagnostic yield in the evaluation of pancreatic masses. The combined molecular analysis increases the number of informative cases without diminishing specificity.

5 Article Endoscopic closure of duodenal perforation with an over-the-scope clip during endoscopic ultrasound-guided cholangiopancreatography. 2012

Salord, Silvia / Gornals, Joan B / Maisterra, Sandra / Pons, Carles / Busquets, Juli / Fabregat, Joan. ·Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. ·Rev Esp Enferm Dig · Pubmed #23130857.

ABSTRACT: -- No abstract --

6 Article [Indications and results of pancreatic metastasis resection. Experience in the Hospital Universitario de Bellvitge]. 2012

Casajoana, Anna / Fabregat, Joan / Peláez, Núria / Busquets, Juli / Valls, Carlos / Leiva, David / Secanella, Lluís / Lladó, Laura / Ramos, Emilio. ·Servicio de Cirugía General y Aparato Digestivo, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España. acbadia@bellvitgehospital.cat ·Cir Esp · Pubmed #22854205.

ABSTRACT: OBJECTIVE: To analyse the indications and results of pancreatic metastasis resection in a university hospital. PATIENTS AND METHODS: An analysis was performed on a prospective database from 1990 to 2010. The clinical-pathological and perioperative details, as well the follow-up results were analysed. RESULTS: Of the 710 pancreatic resections performed, 7 cases (0.99%) were due to a metastasis in the pancreas. The mean age of the patients was 53.3 years (20-77 years), and 5 were male and 2 were women. Five (70%) patients were asymptomatic. The origin of the metastasis was: colon (n=3), kidney (n=2), jejunum (n=1), and testicle (n=1). In 4 cases they were situated in the head, 2 in the tail, and one in the body. The metastases were metachronous in 4 (57%) patients and the disease free interval was 29 months (17-48). There were 3 cases (43%) of synchronous metastases, with a mean recurrence-free time of 14 months, and survival of 21.6 months. This was lower than that of patients with metachronous metastases, which was 27.8 months and with a survival of 32 months, respectively. The overall disease free interval and survival was 21.85 months and 27.5 months, respectively. CONCLUSION: Resection of pancreatic metastases can extend survival in selected patients.